BeiGene, Ltd. - American Depositary Shares (NQ:BGNE)

184.71 UNCHANGED

Last Price Updated: 4:00 PM EST, Dec 31, 2024 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about BeiGene, Ltd. - American Depositary Shares

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

16 17 Next >

BeiGene Announces Strategic Alliance with Ontada to Improve U.S. Community Oncology Care

August 15, 2022

From BeiGene

Via Business Wire

Recap of Tuesday's Biotech Catalysts - End Of the Day Summary ↗

August 09, 2022

Via Benzinga

Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful ↗

August 09, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Recap: BeiGene Q2 Earnings ↗

August 04, 2022

BeiGene (NASDAQ:BGNE) reported its Q2 earnings results on Thursday, August 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings BeiGene reported an EPS of $-5.56.

Via Benzinga

BeiGene Announces Positive Global Phase 3 Trial Results for PD-1 Inhibitor Tislelizumab in First-Line Unresectable Hepatocellular Cancer

August 09, 2022

From BeiGene

Via Business Wire

Coinbase, MercadoLibre And Some Other Big Stocks Recording Gains On Thursday ↗

August 05, 2022

U.S. stocks closed mixed on Thursday following the release of weekly jobless claims data. Here is the list of some big stocks moving higher in the previous session.

Via Benzinga

BeiGene Reports Second Quarter 2022 Financial Results

August 04, 2022

From BeiGene, Ltd.

Via Business Wire

Biotech Investors: August's Key PDUFA Catalysts You Must Know ↗

July 31, 2022

Regulatory decisions have yet to pick up pace this year. July’s calendar was light, but the good news was that most decisions turned out to be positive. That said, none of the drugs approved during the...

Via Benzinga

Beigene's Inspections Delay Suggest Eventual Approval, Says This Analyst ↗

July 14, 2022

Beigene Limited (NASDAQ: BGNE) provided a regulatory update on the anticipated US approval decision for the Biological License Application for tislelizumab in 2L metastatic esophageal squamous cell...

Via Benzinga

U.S. FDA Defers Decision On BeiGene's Filing For Esophageal Carcinoma Due To Pending Inspection ↗

July 14, 2022

The U.S. Food and Drug Administration (FDA) has deferred decision on the Biologics License Application (BLA) for BeiGene’s (NASDAQ: BGNE) tislelizumab as a second-line treatment for patients with...

Via Benzinga

The Daily Biotech Pulse: Much Awaited FDA Nod For Novavax's COVID-19 Shot, DSMB Suggests ContraFect To Stop Antimicrobial-Resistant Infection Study, CytomX Restructures ↗

July 14, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

BeiGene Provides Regulatory Update on the U.S. Biologics License Application (BLA) for PD-1 Inhibitor Tislelizumab in 2L ESCC

July 14, 2022

From BeiGene

Via Business Wire

BeiGene Appoints Chan Lee as General Counsel

July 13, 2022

From BeiGene

Via Business Wire

Week In Review: Sequoia China Raises $9 Billion For Healthcare And Technology Investments ↗

July 09, 2022

New investments in China life science may have declined over the last year, but large investment companies continue to raise large sums to invest. Sequoia China has raised about $9 billion to make...

Via Talk Markets

BeiGene Announces Strategic Research Collaboration with InnoRNA to Jointly Discover Novel mRNA Therapies

July 06, 2022

From BeiGene

Via Business Wire

Week In Review: Henlius Signs $196 Million Deal For Two Oncology Bifunctional Sialidase Candidates ↗

July 02, 2022

Shanghai Henlius Biotech acquired Greater China rights to two early-stage bifunctional sialidase candidates from Palleon Pharma, a Waltham, MA biopharma, in a deal with $196.5 million in development...

Via Talk Markets

Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates ↗

July 01, 2022

The biotech sector is poised to end June on a positive note, despite largely disappointing regulatory decisions scheduled during the month, thanks to a reversal in broader market sentiment.

Via Benzinga

Novartis' Tislelizumab Extends Overall Survival In Late-Stage Esophageal Cancer Study ↗

June 30, 2022

Novartis AG (NYSE: NVS) announced results from the Phase 3 RATIONALE 306 trial of tislelizumab plus chemotherapy in patients with unresectable, locally advanced recurrent or metastatic esophageal...

Via Benzinga

BeiGene Announces Late-Breaking Data at ESMO GI Showing Overall Survival Benefit for Tislelizumab Plus Chemotherapy in First-Line Advanced or Metastatic Esophageal Squamous Cell Carcinoma

June 30, 2022

From BeiGene

Via Business Wire

7 Penny Stocks That Could Triple in 2022 ↗

June 22, 2022

Penny stocks are affordable and some with credible business models in all likelihood have the potential to generate superior returns.

Via InvestorPlace

BeiGene Announces Acceptance of Supplemental Biologics License Application in China for Anti-PD-1 Inhibitor Tislelizumab

June 21, 2022

From BeiGene

Via Business Wire

SpringWorks Therapeutics Shares Jump On HC Wainwright Bullish Pitch ↗

June 13, 2022

HC Wainwright points out that investors are enthusiastic about SpringWorks Therapeutics Inc (NASDAQ: SWTX) nirogacestat clinical profile for desmoid tumors after the R&D day held last week.

Via Benzinga

BeiGene Announces BRUKINSA™ (zanubrutinib) Is Approved in 50 Markets

June 13, 2022

From BeiGene

Via Business Wire

BeiGene Announces PDUFA Goal Date Extension for U.S. sNDA for BRUKINSA for the Treatment of CLL/SLL

June 13, 2022

From BeiGene

Via Business Wire

BeiGene Highlights Growing Portfolio and Pipeline Targeting Hematologic Malignancies at European Hematology Association 2022 Congress

June 10, 2022

From BeiGene

Via Business Wire

China NMPA Approves Tislelizumab for Recurrent or Metastatic Nasopharyngeal Cancer

June 10, 2022

From BeiGene

Via Business Wire

BeiGene to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference

June 08, 2022

From BeiGene

Via Business Wire

BeiGene Clinical Data Presentations at 2022 ASCO Annual Meeting Demonstrate Mature and Growing Oncology Portfolio

May 26, 2022

From BeiGene

Via Business Wire

BeiGene Strengthens European Presence With the Opening of Regional Office in Basel, Switzerland

May 17, 2022

From BeiGene, Ltd.

Via Business Wire

Amid Slowing Sales at Home, Innovent Biologics Stumbles Overseas ↗

May 13, 2022

Key takeaways: Innovent Biologics terminated a plan to sell its bevacizumab biosimilar in North America with a local partner after trials for the drug fell behind schedule The...

Via Benzinga

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

16 17 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.